MICHAELINE BAILEY: Open Payments
NPI 1447890298 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,621 in 83 payments from 16 companies in 2025. Trend: 2023 $634 · 2024 $1,871 · 2025 $1,621
Food & beverage: $1,621
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $454 |
| ABBVIE INC. | 16 | $254 |
| Novo Nordisk Inc | 9 | $167 |
| Corcept Therapeutics | 6 | $146 |
| Lilly USA, LLC | 5 | $76 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 2 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $63 |
| REVANCE THERAPEUTICS, INC. | 2 | $62 |
Products named: FARXIGA, LINZESS, Korlym, AIRSUPRA, Ozempic, JARDIANCE, TRELEGY ELLIPTA, REXULTI.
Industry payments across MS — which companies pay providers there.
